VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses,RSC Medicinal Chemistry

当前位置： X-MOL 学术 › RSC Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses
RSC Medicinal Chemistry ( IF 4.1 ) Pub Date : 2021-07-06 , DOI: 10.1039/d1md00185j
Chenyang Wu ₁ , Xin Cao ₂ , Xiaojin Zhang ₁

Affiliation

V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is a novel negative checkpoint regulator that mediates T cell proliferation and cytokine production. The VISTA signaling pathway blockade has been proved as a promising strategy for cancer immunotherapy. Recent VISTA sequence analysis and crystal structure investigations have revealed its independent and unique function as compared with B7 family members, such as PD-1. This review will discuss VISTA binding partners and compare the structural differences between VISTA and other B7 family members, focusing on VISTA functions in immune activation and maintaining T cell quiescence. Recent progress and the therapeutic potential of biomacromolecules, such as monoclonal antibodies (mAbs) and small molecules targeting VISTA, are also discussed. Among these, a first-in-class small-molecule antagonist, CA-170, is highlighted.

中文翻译：

VISTA 抑制剂在癌症免疫治疗中的应用：近期进展简述

T 细胞激活的 V 域免疫球蛋白 (Ig) 抑制因子 (VISTA) 是一种新型负检查点调节因子，可介导 T 细胞增殖和细胞因子产生。 VISTA 信号通路阻断已被证明是一种有前途的癌症免疫治疗策略。最近的VISTA序列分析和晶体结构研究揭示了其与B7家族成员（例如PD-1）相比独立且独特的功能。本综述将讨论 VISTA 结合伴侣并比较 VISTA 与其他 B7 家族成员之间的结构差异，重点关注 VISTA 在免疫激活和维持 T 细胞静止中的功能。还讨论了单克隆抗体 (mAb) 和靶向 VISTA 的小分子等生物大分子的最新进展和治疗潜力。其中，首创的小分子拮抗剂CA-170备受瞩目。

更新日期：2021-08-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文